Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1661

Apr 17, 2020

Coronavirus test using CRISPR detects disease in under 40 minutes

Posted by in category: biotech/medical

The new diagnostic tool, Detectr, shows promise in rapidly detecting COVID-19.

Apr 17, 2020

In the Future, Human Cloning Might Mean Giving Birth to Your Own Sibling

Posted by in categories: biotech/medical, futurism

Human clones have long been a topic of science fiction, but how far off are they in reality? Let’s take a look at current advances and see when and where we might see the first human clone.

Apr 17, 2020

New clues to predict the risks astronauts will face from space radiation on long missions

Posted by in categories: biotech/medical, genetics, health

The National Aeronautics and Space Administration, NASA, aims to send human missions to Mars in the 2030s. But scientists are still trying to learn more about the potential cancer risks for astronauts due to radiation exposure. Cancer risk from galactic cosmic radiation exposure is considered a potential “showstopper” for a manned mission to Mars.

A team led by researchers at Colorado State University used a novel approach to test assumptions in a model used by NASA to predict these . The NASA model predicts that astronauts will have more than a three percent risk of dying of from the exposures they will receive on a Mars mission. That level of risk exceeds what is considered acceptable.

The study, “Genomic mapping in outbred mice reveals overlap in genetic susceptibility for HZE ion- and gamma-ray-induced tumors,” was published April 15 in Science Advances.

Apr 17, 2020

Moscow’s Facial Recognition Tech Will Outlast the Coronavirus

Posted by in categories: biotech/medical, robotics/AI, surveillance

👽 Facial recognition and Covid 19 in Moscow, Russia.

Fyodor R.

Continue reading “Moscow’s Facial Recognition Tech Will Outlast the Coronavirus” »

Apr 17, 2020

What do we know about COVID-19 and sewage?

Posted by in categories: biotech/medical, health, surveillance

A version of this story was first published by COVID-19 Waterblog. Read the original.

There has been quite some talk about SARS-CoV-2 shedding in faeces and what that might mean for the water industry. Here, Susan Petterson provides a snapshot of the current data.

As I see it, there are two aspects to this conversation: the first is a concern that sewage may contain infectious SARS-CoV-2 viruses; and the second relates to the more theoretical potential of using SARS-CoV-2 RNA concentration in sewage as a public health surveillance tool.

Apr 17, 2020

Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)

Posted by in category: biotech/medical

Lysergic acid diethylamide (LSD) is a prototypical serotonergic psychedelic drug and the subject of many clinical investigations. In recent years, a range of lysergamides has emerged with the production of some being inspired by the existing scientific literature. Others, for example various 1-acyl substituted lysergamides, did not exist before their appearance as research chemicals. 1-Cylopropanoyl-LSD (1CP-LSD) has recently emerged as a new addition to the group of lysergamide-based designer drugs and is believed to be psychoactive in humans. In this investigation, 1CP-LSD was subjected to detailed analytical characterizations including various mass spectrometry (MS) platforms, gas and liquid chromatography, nuclear magnetic resonance spectroscopy, solid phase and GC condensed phase infrared spectroscopy. Analysis by GC-MS also revealed the detection of artificially induced degradation products. Incubation of 1CP-LSD with human serum led to the formation of LSD, indicating that it may act as a prodrug for LSD in vivo, similar to other 1-acyl substituted lysergamides. The analysis of blotters and pellets is also included. 1CP-LSD also induces the head-twitch response (HTR) in C57BL/6J mice, indicating that it produces an LSD-like behavioural profile. 1CP-LSD induced the HTR with an ED50 = 430.0 nmol/kg which was comparable with 1P-LSD (ED50 = 349.6 nmol/kg) investigated previously. Clinical studies are required to determine the potency and profile of effects produced by 1CP-LSD in humans.

This article is protected by copyright. All rights reserved.

PMID: 32180350 DOI: 10.1002/dta.

Apr 17, 2020

Frontiers & IUIS Collaborate on COVID-19 Video & Webinar Series

Posted by in category: biotech/medical

Faith Osier, President of the IUIS — International Union of Immunological Societies, calls on researchers to share knowledge and resources to halt the coronavirus (COVID-19) pandemic, as she launches an expert commentary and webinar series on scientific and civil responses to the outbreak.

See all interviews: https://fro.ntiers.in/yDH4

Apr 17, 2020

After Anonymous Tip, 17 Bodies Found at Nursing Home Hit by Virus

Posted by in category: biotech/medical

There have been 68 recent deaths of residents and nurses from the facility in a small New Jersey town.

Apr 17, 2020

‘DO NOT click the link’; Police warn of scam COVID-19 text messages

Posted by in categories: biotech/medical, cybercrime/malcode, mobile phones

Scam alert.


THOMASTON, Me. (WSET) — Police are warning cell phone users of a new text message scam during the coronavirus pandemic. The Thomaston Police Department in Maine posted on Facebook a photo of the alert being sent to people in a text message. The message was sent to someone in Maine from an Indiana area code telling them they need to self-isolate because they came in contact with someone who tested positive or has shown symptoms for coronavirus. The alert also tells you to get tested.

Apr 16, 2020

MDMA-Assisted Psychotherapy

Posted by in categories: biotech/medical, education, law, neuroscience

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501©(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: Developing psychedelics and marijuana into prescription medicines; Training therapists and working to establish a network of treatment centers; Supporting scientific research into spirituality, creativity, and neuroscience; and educating the public honestly about the risks and benefits of psychedelics and marijuana.